Wells Fargo Maintains Overweight on Nurix Therapeutics, Raises Price Target to $30

Benzinga · 1d ago
Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $21 to $30.